Developer docs
API playgroundTry for free, no card

Search company profiles

Spiral Therapeutics

Full company profile

uuid0002fmb

Namestring
Spiral Therapeutics
Legal namestring
Spiral Therapeutics, Inc.
Websiteurl
spiraltx.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Spiral Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing therapeutics for inner ear disorders with an initial focus on Ménière's disease and broader hearing-loss indications. The company's core technology is the proprietary MICS™ (Minimally-Invasive Cochlear System) drug-delivery platform, which combines what the company describes as the world's smallest clinical microendoscope for the ear with sustained-release crosslinking gel formulations to deliver anti-inflammatory, otoprotective, and neuroprotective drugs directly to the round window membrane of the cochlea, achieving an estimated two months of continuous drug exposure from a single administration in a clinic setting. Its lead program, SPT-2101 (a 6% dexamethasone sustained-release formulation), completed a Phase 1b/2a trial in 21 Ménière's disease patients across Australia in September 2024, reporting statistically significant reductions in vertigo frequency and severity (p<0.05), a 78.7% reduction in Definitive Vertigo Days at Month 3 in placebo crossover patients, no serious adverse events, and no negative impact on hearing.

Spiral's pipeline beyond SPT-2101 includes the OTO-510 otoprotectant and OTO-413 sustained-exposure BDNF programs acquired from Otonomy, Inc. in March 2023 alongside OTO-104 (OTIVIDEX) data and patent rights, with the company targeting the 600,000+ US Ménière's disease population and a 40M US hearing-loss treatment-eligible population where, per the company, no FDA-approved drug treatments currently exist. The business model is pre-commercial: Spiral has raised roughly $40M+ in venture capital across multiple rounds (most recently a $27M Series B in April 2026 led by Gund Investment with strategic participation from Advanced Bionics and an unnamed global pharma) and plans future revenue from specialty pharmaceutical sales targeting neurotology/ENT prescribers post-approval, supplemented by potential licensing, royalty, or co-development economics from its strategic R&D collaboration with Advanced Bionics (a Sonova subsidiary) for drug-device bundling with cochlear implant procedures. Go-to-market currently relies on scientific conference participation, KOL engagement, patient advocacy partnerships (VeDA), and press release-driven visibility rather than direct sales.

Short descriptiontext

Spiral Therapeutics is a clinical-stage biopharmaceutical company developing minimally invasive, sustained-release drug therapies for inner ear disorders, with a lead program (SPT-2101) targeting Ménière's disease and a proprietary MICS™ delivery platform for broader hearing-loss indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
inner ear therapeutics, cochlear drug delivery, Ménière's disease treatment, otology pharmaceuticals, hearing loss therapeutics
Industry1 code
PRIMARYHLAKAMAC
Otology & Neurotology (Ear/Hearing/Balance)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Otology Pharmaceuticals — Inner Ear Therapeutics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pre-revenue Clinical Development
TypeSubscription Recurring
Description

Spiral is a clinical-stage biotechnology company with no products currently approved or commercialized. Revenue is not yet generated; future revenue will come from commercialization of SPT-2101 (and broader pipeline) once registrational trials and regulatory approvals are secured for inner ear disorder indications.

spiraltx.com
2Future Pharmaceutical Product Sales
TypeHardware Sales
Description

Upon approval, SPT-2101 (long-acting dexamethasone for Meniere's disease) is expected to generate specialty pharmaceutical revenue targeting neurotology/ENT prescribers and their patients; broader pipeline (including neurotrophic approaches) will contribute additional product revenue.

spiraltx.com
3Strategic R&D Collaboration / Future Co-Commercialization
TypeLicensing Royalties
Description

R&D collaboration with Advanced Bionics (cochlear implant leader) creates a pathway toward joint development of drug-delivery solutions for cochlear implant recipients, which may include future co-commercialization, licensing, or royalty structures.

hearingreview.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Not publicly disclosed (pre-commercial clinical-stage biotech)
ModelOther
Notes

No pricing information available; SPT-2101 has not yet been approved or marketed. Quote-based / Not publicly disclosed.

spiraltx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Spiral Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of therapeutics for inner ear disorders, anchored by its proprietary MICS™ (Minimally-Invasive Cochlear System) drug delivery platform that enables minimally invasive, precise, and durable delivery of drugs to the cochlea. The lead program, SPT-2101, is a 6% dexamethasone sustained-release gel formulation delivered via MICS™ to the round window membrane for the treatment of Ménière's disease, with a broader pipeline including neurotrophic and otoprotective approaches for hearing loss.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Statistically significant reduction in vertigo frequency and severity in Meniere's disease patients (p<0.05)
+4 more records
Product overview1 text field

Spiral Therapeutics is a clinical-stage biopharmaceutical company offering a platform-plus-candidates product architecture: its core MICS™ (Minimally-Invasive Cochlear System) drug delivery platform underpins a pipeline of inner ear therapeutics. The lead program, SPT-2101, is a sustained-release 6% dexamethasone formulation delivered precisely to the round window membrane via MICS™ for the treatment of Meniere's disease, having demonstrated statistically significant vertigo reduction in Phase 1b/2a and advancing toward a registrational trial. Beyond SPT-2101, the company is advancing neurotrophic hearing loss programs (e.g., neurotrophic approaches targeting fundamental disease pathobiology) and the acquired Otonomy assets OTO-104 (OTIVIDEX), OTO-510, and OTO-413, all leveraging the MICS™ delivery technology. Strategic R&D collaboration with Advanced Bionics extends MICS™ into sustained local drug delivery at the time of cochlear implantation.

Product and service4 records
1SPT-2101
CategoryLead drug candidate (clinical-stage)
Description

Clinical-stage lead drug candidate: a sustained-release 6% dexamethasone crosslinking gel formulation designed for precise intratympanic delivery to the round window membrane via Spiral's MICS™ platform to treat Ménière's disease. Demonstrated statistically significant reduction in vertigo frequency and severity in Phase 1b/2a (p<0.05) with no SAEs and no negative impact on hearing.

2OTO-104 (OTIVIDEX)
CategoryAcquired asset (from Otonomy)
Description

Sustained-exposure formulation of dexamethasone acquired from Otonomy for Ménière's disease. Spiral acquired the data and a right of reference to support SPT-2101's late-stage clinical development and pathway.

3OTO-510
CategoryAcquired asset (from Otonomy)
Description

Otoprotectant program acquired from Otonomy, Inc., including patent rights, data, and know-how. Part of Spiral's expanded inner-ear disorders pipeline beyond SPT-2101.

4OTO-413
CategoryAcquired asset (from Otonomy)
Description

Sustained-exposure formulation of Brain-Derived Neurotrophic Factor (BDNF) acquired from Otonomy, Inc., along with preclinical and clinical data and inventory. Part of Spiral's neurotrophic approaches to inner-ear disorders.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagship Strategic PartnerTypeStrategic or Co-development PartnerAnnounced on2026-04-15
Description

Advanced Bionics (AB), a developer of cochlear implant technology and a subsidiary of Sonova Group, announced an equity investment and R&D collaboration with Spiral Therapeutics. The collaboration will explore integrating Spiral's MICS drug-delivery platform with AB's cochlear implant development to investigate sustained local drug delivery at the time of cochlear implantation. The partnership combines AB's global leadership in cochlear implant technology with Spiral's expertise in novel therapeutics for inner ear disorders, representing an early-stage R&D effort with potential future patient benefits.

Strategic tierPatient Advocacy PartnershipTypeGTM or Marketing PartnerAnnounced on2023-10-31
Description

Spiral entered a strategic partnership with the Vestibular Disorders Association (VeDA) to improve the lives of patients with balance disorders such as Meniere's Disease. The collaboration grants Spiral access to VeDA's Patient Registry on Meniere's patients and facilitates targeted outreach to Meniere's clinicians and patients in the United States and Australia, plus co-developed patient education programs (including placebo-effect education).

3Otonomy, Inc.
Strategic tierAsset Acquisition Partner (One-Time)TypeStrategic or Co-development PartnerAnnounced on2023-03-29
Description

In March 2023, Spiral acquired selected assets from Otonomy following Otonomy's stockholder-approved dissolution. The transaction included preclinical and clinical data, patent rights, data, know-how, and inventory related to OTO-104 (OTIVIDEX, sustained-exposure dexamethasone), OTO-510 (otoprotectant), and OTO-413 (sustained-exposure BDNF). Spiral also obtained a right of reference to OTO-104 data, leveraging Otonomy's 15 years of inner ear disorder experience to accelerate SPT-2101's path to late-stage trials.

spiraltx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global cochlear implant market leader and Advanced Bionics' main competitor. Comparable as a hearing-loss treatment incumbent and the most likely alternative bundled-implant-plus-drug partner if Advanced Bionics collaboration does not deliver.

TypeBroad incumbent
Description

Global cochlear and hearing implant manufacturer. Comparable to the Advanced Bionics side of Spiral's strategic channel and a potential alternative partner for any drug-delivery-plus-implant therapy.

3Sound Pharmaceuticals
TypeDirect peer
Description

Clinical-stage biopharma developing novel therapeutics (e.g., SPI-1005, SPI-3005) for hearing loss, tinnitus, and ototoxicity. Comparable as an inner-ear-focused small-molecule biotech targeting similar indications with novel drug candidates.

TypeBroad incumbent
Description

Hearing implant business of Demant, a major audiology conglomerate. Comparable to the Advanced Bionics collaboration partner as another large hearing-implant incumbent that could pursue a bundled drug-device model in cochlear implantation.

TypeEmerging player
Description

German clinical-stage biotech developing small-molecule therapeutics (e.g., ACOU085) for sensorineural hearing loss and otoprotection. Comparable in therapeutic area and modality, though earlier-stage and with a different delivery approach.

TypeDirect peer
Description

Clinical-stage regenerative medicine company developing therapies for hearing loss (FX-322). Directly comparable in targeting hearing restoration with a novel inner-ear modality and a similar clinical-stage risk/reward profile.

7Otonomy, Inc. (historical)
TypeDirect peer
Description

Previously a leading clinical-stage inner-ear therapeutics company (OTO-104, OTO-413) that dissolved in 2023 after a series of clinical setbacks. Spiral acquired its assets and is the de-facto successor; highly comparable historical peer in both technology (sustained-exposure steroid) and indication focus.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics for hearing loss and inner-ear disorders (gene therapy for OTOF, etc.); historically the most direct peer to Spiral in the inner-ear therapeutic space before being acquired by Regeneron in 2023. Highly comparable therapeutic focus and patient population.

TypeDirect peer
Description

Clinical-stage biotech developing small-molecule therapeutics for inner-ear disorders including hearing loss and balance disorders. Closely comparable in mechanism (small-molecule inner-ear targeting) and clinical stage to Spiral.

TypeRegional player
Description

Japan-listed specialty pharmaceutical company with a focus on otolaryngology and inner-ear disorders, including Meniere's disease therapies. Comparable as a regional player in the Meniere's therapeutics market that Spiral ultimately targets in the US.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spiral Therapeutics

Otology Pharmaceuticals — Inner Ear Therapeuticsspiraltx.com

Spiral Therapeutics is a clinical-stage biopharmaceutical company developing minimally invasive, sustained-release drug therapies for inner ear disorders, with a lead program (SPT-2101) targeting Ménière's disease and a proprietary MICS™ delivery platform for broader hearing-loss indications.

What Spiral Therapeutics does

Spiral Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing therapeutics for inner ear disorders with an initial focus on Ménière's disease and broader hearing-loss indications. The company's core technology is the proprietary MICS™ (Minimally-Invasive Cochlear System) drug-delivery platform, which combines what the company describes as the world's smallest clinical microendoscope for the ear with sustained-release crosslinking gel formulations to deliver anti-inflammatory, otoprotective, and neuroprotective drugs directly to the round window membrane of the cochlea, achieving an estimated two months of continuous drug exposure from a single administration in a clinic setting. Its lead program, SPT-2101 (a 6% dexamethasone sustained-release formulation), completed a Phase 1b/2a trial in 21 Ménière's disease patients across Australia in September 2024, reporting statistically significant reductions in vertigo frequency and severity (p<0.05), a 78.7% reduction in Definitive Vertigo Days at Month 3 in placebo crossover patients, no serious adverse events, and no negative impact on hearing.

Spiral's pipeline beyond SPT-2101 includes the OTO-510 otoprotectant and OTO-413 sustained-exposure BDNF programs acquired from Otonomy, Inc. in March 2023 alongside OTO-104 (OTIVIDEX) data and patent rights, with the company targeting the 600,000+ US Ménière's disease population and a 40M US hearing-loss treatment-eligible population where, per the company, no FDA-approved drug treatments currently exist. The business model is pre-commercial: Spiral has raised roughly $40M+ in venture capital across multiple rounds (most recently a $27M Series B in April 2026 led by Gund Investment with strategic participation from Advanced Bionics and an unnamed global pharma) and plans future revenue from specialty pharmaceutical sales targeting neurotology/ENT prescribers post-approval, supplemented by potential licensing, royalty, or co-development economics from its strategic R&D collaboration with Advanced Bionics (a Sonova subsidiary) for drug-device bundling with cochlear implant procedures. Go-to-market currently relies on scientific conference participation, KOL engagement, patient advocacy partnerships (VeDA), and press release-driven visibility rather than direct sales.

Spiral Therapeutics firmographics

Firmographics
Name
Spiral Therapeutics
Legal name
Spiral Therapeutics, Inc.
Website
https://spiraltx.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Spiral Therapeutics is a clinical-stage biopharmaceutical company developing minimally invasive, sustained-release drug therapies for inner ear disorders, with a lead program (SPT-2101) targeting Ménière's disease and a proprietary MICS™ delivery platform for broader hearing-loss indications.
Ownership category
akta.pro rank

Spiral Therapeutics industry classification

Industry
Product category
Otology Pharmaceuticals — Inner Ear Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAKAMAC
Otology & Neurotology (Ear/Hearing/Balance)

Keywords

  • Inner ear therapeutics
  • Cochlear drug delivery
  • Ménière's disease treatment
  • Otology pharmaceuticals
  • Hearing loss therapeutics

Where Spiral Therapeutics is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Spiral Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pre-revenue Clinical Development: Spiral is a clinical-stage biotechnology company with no products currently approved or commercialized. Revenue is not yet generated; future revenue will come from commercialization of SPT-2101 (and broader pipeline) once registrational trials and regulatory approvals are secured for inner ear disorder indications.
  2. Future Pharmaceutical Product Sales: Upon approval, SPT-2101 (long-acting dexamethasone for Meniere's disease) is expected to generate specialty pharmaceutical revenue targeting neurotology/ENT prescribers and their patients; broader pipeline (including neurotrophic approaches) will contribute additional product revenue.
  3. Strategic R&D Collaboration / Future Co-Commercialization: R&D collaboration with Advanced Bionics (cochlear implant leader) creates a pathway toward joint development of drug-delivery solutions for cochlear implant recipients, which may include future co-commercialization, licensing, or royalty structures.

Pricing tiers

ModelBillingPrice
Other—Not publicly disclosed (pre-commercial clinical-stage biotech)

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Spiral Therapeutics product offering

Product offering

Core offering

Spiral Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of therapeutics for inner ear disorders, anchored by its proprietary MICS™ (Minimally-Invasive Cochlear System) drug delivery platform that enables minimally invasive, precise, and durable delivery of drugs to the cochlea. The lead program, SPT-2101, is a 6% dexamethasone sustained-release gel formulation delivered via MICS™ to the round window membrane for the treatment of Ménière's disease, with a broader pipeline including neurotrophic and otoprotective approaches for hearing loss.

Product overview

Spiral Therapeutics is a clinical-stage biopharmaceutical company offering a platform-plus-candidates product architecture: its core MICS™ (Minimally-Invasive Cochlear System) drug delivery platform underpins a pipeline of inner ear therapeutics. The lead program, SPT-2101, is a sustained-release 6% dexamethasone formulation delivered precisely to the round window membrane via MICS™ for the treatment of Meniere's disease, having demonstrated statistically significant vertigo reduction in Phase 1b/2a and advancing toward a registrational trial. Beyond SPT-2101, the company is advancing neurotrophic hearing loss programs (e.g., neurotrophic approaches targeting fundamental disease pathobiology) and the acquired Otonomy assets OTO-104 (OTIVIDEX), OTO-510, and OTO-413, all leveraging the MICS™ delivery technology. Strategic R&D collaboration with Advanced Bionics extends MICS™ into sustained local drug delivery at the time of cochlear implantation.

Differentiator

Problem solved

Functional benefit

Products and services

  • SPT-2101 Clinical-stage lead drug candidate: a sustained-release 6% dexamethasone crosslinking gel formulation designed for precise intratympanic delivery to the round window membrane via Spiral's MICS™ platform to treat Ménière's disease. Demonstrated statistically significant reduction in vertigo frequency and severity in Phase 1b/2a (p<0.05) with no SAEs and no negative impact on hearing.
  • OTO-104 (OTIVIDEX) Sustained-exposure formulation of dexamethasone acquired from Otonomy for Ménière's disease. Spiral acquired the data and a right of reference to support SPT-2101's late-stage clinical development and pathway.
  • OTO-510 Otoprotectant program acquired from Otonomy, Inc., including patent rights, data, and know-how. Part of Spiral's expanded inner-ear disorders pipeline beyond SPT-2101.
  • OTO-413 Sustained-exposure formulation of Brain-Derived Neurotrophic Factor (BDNF) acquired from Otonomy, Inc., along with preclinical and clinical data and inventory. Part of Spiral's neurotrophic approaches to inner-ear disorders.

Quantifiable outcome

  • Statistically significant reduction in vertigo frequency and severity in Meniere's disease patients (p<0.05)
  • +4 more outcomes

Companies that use Spiral Therapeutics

Customer profile

Segments4 records

Ideal customer profiles4 records

Spiral Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Spiral Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship strategic partner, patient advocacy partnership and asset acquisition partner (one-time).

  • Advanced Bionics (Sonova Group)flagship strategic partnerStrategic or Co-development Partner · 15 April 2026Advanced Bionics (AB), a developer of cochlear implant technology and a subsidiary of Sonova Group, announced an equity investment and R&D collaboration with Spiral Therapeutics. The collaboration will explore integrating Spiral's MICS drug-delivery platform with AB's cochlear implant development to investigate sustained local drug delivery at the time of cochlear implantation. The partnership combines AB's global leadership in cochlear implant technology with Spiral's expertise in novel therapeutics for inner ear disorders, representing an early-stage R&D effort with potential future patient benefits.
  • Vestibular Disorders Association (VeDA)patient advocacy partnershipGTM or Marketing Partner · 31 October 2023Spiral entered a strategic partnership with the Vestibular Disorders Association (VeDA) to improve the lives of patients with balance disorders such as Meniere's Disease. The collaboration grants Spiral access to VeDA's Patient Registry on Meniere's patients and facilitates targeted outreach to Meniere's clinicians and patients in the United States and Australia, plus co-developed patient education programs (including placebo-effect education).
  • Otonomy, Inc.asset acquisition partner (one-time)Strategic or Co-development Partner · 29 March 2023In March 2023, Spiral acquired selected assets from Otonomy following Otonomy's stockholder-approved dissolution. The transaction included preclinical and clinical data, patent rights, data, know-how, and inventory related to OTO-104 (OTIVIDEX, sustained-exposure dexamethasone), OTO-510 (otoprotectant), and OTO-413 (sustained-exposure BDNF). Spiral also obtained a right of reference to OTO-104 data, leveraging Otonomy's 15 years of inner ear disorder experience to accelerate SPT-2101's path to late-stage trials.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Spiral Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Cochlear Limited: Global cochlear implant market leader and Advanced Bionics' main competitor. Comparable as a hearing-loss treatment incumbent and the most likely alternative bundled-implant-plus-drug partner if Advanced Bionics collaboration does not deliver.
  • MED-EL: Global cochlear and hearing implant manufacturer. Comparable to the Advanced Bionics side of Spiral's strategic channel and a potential alternative partner for any drug-delivery-plus-implant therapy.
  • Oticon Medical (Demant): Hearing implant business of Demant, a major audiology conglomerate. Comparable to the Advanced Bionics collaboration partner as another large hearing-implant incumbent that could pursue a bundled drug-device model in cochlear implantation.

Direct peers

  • Sound Pharmaceuticals: Clinical-stage biopharma developing novel therapeutics (e.g., SPI-1005, SPI-3005) for hearing loss, tinnitus, and ototoxicity. Comparable as an inner-ear-focused small-molecule biotech targeting similar indications with novel drug candidates.
  • Frequency Therapeutics: Clinical-stage regenerative medicine company developing therapies for hearing loss (FX-322). Directly comparable in targeting hearing restoration with a novel inner-ear modality and a similar clinical-stage risk/reward profile.
  • Otonomy, Inc. (historical): Previously a leading clinical-stage inner-ear therapeutics company (OTO-104, OTO-413) that dissolved in 2023 after a series of clinical setbacks. Spiral acquired its assets and is the de-facto successor; highly comparable historical peer in both technology (sustained-exposure steroid) and indication focus.
  • Decibel Therapeutics: Clinical-stage biotech developing therapeutics for hearing loss and inner-ear disorders (gene therapy for OTOF, etc.); historically the most direct peer to Spiral in the inner-ear therapeutic space before being acquired by Regeneron in 2023. Highly comparable therapeutic focus and patient population.
  • Pipeline Therapeutics: Clinical-stage biotech developing small-molecule therapeutics for inner-ear disorders including hearing loss and balance disorders. Closely comparable in mechanism (small-molecule inner-ear targeting) and clinical stage to Spiral.

Emerging players

  • Acousia Therapeutics: German clinical-stage biotech developing small-molecule therapeutics (e.g., ACOU085) for sensorineural hearing loss and otoprotection. Comparable in therapeutic area and modality, though earlier-stage and with a different delivery approach.

Regional players

  • Kyorin Pharmaceutical: Japan-listed specialty pharmaceutical company with a focus on otolaryngology and inner-ear disorders, including Meniere's disease therapies. Comparable as a regional player in the Meniere's therapeutics market that Spiral ultimately targets in the US.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Spiral Therapeutics social profiles

Digital presence

Spiral Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spiral Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Spiral Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Spiral Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spiral Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spiral Therapeutics

What does Spiral Therapeutics do?

Spiral Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of therapeutics for inner ear disorders, anchored by its proprietary MICS™ (Minimally-Invasive Cochlear System) drug delivery platform that enables minimally invasive, precise, and durable delivery of drugs to the cochlea. The lead program, SPT-2101, is a 6% dexamethasone sustained-release gel formulation delivered via MICS™ to the round window membrane for the treatment of Ménière's disease, with a broader pipeline including neurotrophic and otoprotective approaches for hearing loss.

Is Spiral Therapeutics a public or private company?

Spiral Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Spiral Therapeutics founded?

Spiral Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Spiral Therapeutics based?

Spiral Therapeutics is headquartered in South San Francisco, United States, in the North America region.

How does Spiral Therapeutics make money?

Three revenue lines are on record. Pre-revenue Clinical Development is the primary driver. The others are future Pharmaceutical Product Sales and strategic R&D Collaboration / Future Co-Commercialization.

Who are Spiral Therapeutics's main competitors?

Broad incumbents on record are Cochlear Limited, MED-EL and Oticon Medical (Demant). Direct peers are Sound Pharmaceuticals, Frequency Therapeutics, Otonomy, Inc. (historical), Decibel Therapeutics and Pipeline Therapeutics. Acousia Therapeutics is listed as an emerging player. Kyorin Pharmaceutical is listed as a regional player.

Does Spiral Therapeutics have an API?

No public API is recorded for Spiral Therapeutics.

What industry is Spiral Therapeutics in?

Spiral Therapeutics's product category is Otology Pharmaceuticals — Inner Ear Therapeutics. Its primary akta.pro industry code is HLAKAMAC, Otology & Neurotology (Ear/Hearing/Balance). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Hearing ReviewAdvanced Bionics Announces Research Collaboration with Spiral TherapeuticsAdvanced Bionics (AB), a developer of cochlear implant technology and subsidiary of Sonova Group, has announced an equity investment and research collaboration with Spiral Therapeutics to explore integrating Spiral's drug-delivery platform with AB's cochlear implant development. The partnership will focus on investigating how Spiral's platform, designed for minimally invasive and precise delivery of therapeutics to the cochlea, could be utilized during cochlear implant surgery to address unmet needs in the field. The collaboration represents an early-stage R&D effort combining both companies' complementary capabilities for potential future patient benefits.Pulse 2.0Spiral Therapeutics: $27 Million Series B And Advanced Bionics Partnership Advance Inner Ear TherapiesSpiral Therapeutics announced the close of a $27 million Series B financing round led by Gund Investment, with participation from Advanced Bionics and continued backing from Ferring Ventures and Uni-Bio Science Group. Concurrent with the funding, Spiral entered into a strategic R&D collaboration with Advanced Bionics to explore sustained local drug delivery at the time of cochlear implantation. The proceeds will support advancement of Spiral's lead candidate SPT-2101, which has demonstrated statistically significant reduction in vertigo among Ménière's disease patients, and further development of its MICS drug delivery platform.YahooSpiral Therapeutics Announces $27 Million Series B Financing and Strategic Partnership with Advanced BionicsSpiral Therapeutics, a clinical-stage company developing therapies for inner ear disorders, closed a $27 million Series B financing round led by Gund Investment, with new strategic participation from Advanced Bionics and a major global pharmaceutical company alongside existing investors Ferring Ventures and Uni-Bio Science Group. Concurrent with the financing, Spiral entered into a strategic R&D collaboration with Advanced Bionics to develop sustained local drug delivery at the time of cochlear implantation to improve outcomes for recipients. The proceeds will support advancement of Spiral's lead program SPT-2101, which demonstrated statistically significant reduction in vertigo for Ménière's disease patients and is preparing for a registrational trial, as well as expansion of the MICS™ drug delivery platform.PR NewswireSpiral Therapeutics Announces $27 Million Series B Financing and Strategic Partnership with Advanced BionicsSpiral Therapeutics, a clinical-stage biotech focused on inner ear disorders, closed a $27 million Series B financing round led by Gund Investment, with new strategic participation from Advanced Bionics and an unnamed major global pharmaceutical company. Concurrent with the financing, Spiral entered an R&D collaboration with Advanced Bionics to develop sustained local drug delivery solutions for cochlear implant recipients. Proceeds will fund the registrational trial for lead program SPT-2101, which demonstrated statistically significant vertigo reduction in Ménière's disease patients, and expansion of the proprietary MICS drug delivery platform.Venture Capital Access OnlineSpiral Therapeutics Announces $27 Million Series B Financing and Strategic Partnership with Advanced BionicsSpiral Therapeutics closed a $27 million Series B financing led by Gund Investment, with Advanced Bionics and a major pharmaceutical company joining as strategic investors. The company also entered an R&D collaboration with Advanced Bionics to explore drug delivery at cochlear implantation. Proceeds will support its pipeline, including SPT-2101 and the MICS platform.TechStartupsSecurity Risk Advisors Purple Team Participants Can Now Earn CPE CreditsSecurity Risk Advisors announced that its Purple Team exercises now earn CPE credits from GIAC and ISC2. Each 15-hour engagement yields up to 15 CPE credits per participant, with certificates issued from April 2026. Participants must attend at least 80% of sessions.TechStartupsTop Startup and Tech Funding News – April 14 2025On April 14, 2026, multiple startups raised funding across AI infrastructure, biotech, and enterprise software. Glydways led with a $170M Series C, followed by Sygaldry's $105M Series A and nEye.ai's $80M Series C. The rounds signal investor focus on AI infrastructure and agentic systems.TechStartupsAmazon acquires Globalstar for $11.6B, taking direct aim at SpaceX’s StarlinkAmazon agreed to acquire satellite operator Globalstar for about $11.57 billion, integrating its operations into its Leo satellite internet program. The deal, expected to close in 2027, gives Amazon control of Globalstar's spectrum and infrastructure, aiming to roll out direct-to-device connectivity by 2028. The acquisition puts Amazon on a direct collision course with SpaceX's Starlink, which leads the market.TechStartupsnEye.ai raises $80M to scale optical circuit switching for AI data centersnEye.ai raised $80 million in a Series C round led by Sutter Hill Ventures, bringing total funding to $152 million. The startup will use the capital to scale its optical circuit switching technology for AI data centers, targeting a foundry-based manufacturing model. The company plans to shift focus to high-volume production and meet hyperscaler performance standards.FinSMEsSpiral Therapeutics Raises $27M in Series B FundingSpiral Therapeutics raised $27M in Series B funding led by Gund Investment, with participation from Advanced Bionics and others. The company will use the funds to advance its pipeline, including SPT-2101 and its MICS drug delivery platform, and entered a strategic R&D collaboration with Advanced Bionics.